Phase II study of biweekly cetuximab plus irinotecan for unresectable colorectal cancer

ABSTRACT: Interventions: Biweekly cetuximab plus irinotecan Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2617437 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR